About this episode
The episode discusses the challenges of IPF and fibrosis, featuring insights from industry experts on treatment hurdles and emerging targets.
In this episode of Denatured, you'll be hearing from Georg Vo Beiske, CEO of Tribune Therapeutics and Jonas Hallén, co-founder & Chief Medical Officer of Calluna Pharma. We dive into IPF and fibrosis challenges, unpacking treatment hurdles, emerging targets, unmet needs and expansion paths beyond the lung. Host Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Georg Vo Beiske , CEO, Tribune Therapeutics Jonas Hallén , Co-Founder & CMO, Calluna Pharma Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
People in this episode
Host: Jennifer C. Smith-Parker
Guests: Georg Vo Beiske, Jonas Hallén
Topics covered
- fibrosis
- IPF
- treatment hurdles
- emerging targets
- unmet needs
- lung expansion
Keywords
- fibrosis
- IPF
- Tribune Therapeutics
- Calluna Pharma
- treatment
- emerging targets
- unmet needs
Mentioned in this episode
Organizations: Tribune Therapeutics, Calluna Pharma
More episodes of BioSpace
- Portugal, Spain and the new biotech frontier · June 10, 2026 · 21 min
- Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence · June 10, 2026 · 25 min
- Rethinking hair loss treatment · June 3, 2026 · 22 min
- ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck · June 3, 2026 · 27 min
- France’s biotech ecosystem: science, capital and scale · May 28, 2026 · 21 min
- Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds · May 27, 2026 · 25 min
Explore listener stats, chart rankings, contacts and more on the BioSpace podcast page.